Browsing tag:

Linagliptin


A new study reveals that patients diagnosed with Type2-diabetes are at an increased risk of developing macrovascular and microvascular complications. Researchers are currently using a drug called Linagliptin which is an anti-diabetic drug that works by increasing the levels of incretins to help control blood sugar levels, especially after meals. According to reports, the cardiovascular[…]

Read More

Eli Lilly and Company and Boehringer Ingelheim Pharmaceuticals, Inc. announced on March 19, 2013 the initiation of a novel clinical trial for linagliptin. Coined MARLINA, this Phase IIIb trial will evaluate the glycemic efficacy and safety of linagliptin in patients with type 2 diabetes who have prevalent albuminuria. This patient population, suffering from albuminuria, will[…]

Read More

As a chronic disease which occurs when the body does not properly produce, or use the hormone insulin, type 2 diabetes has become a worldwide problem. Roughly 25.8 million Americans and an estimated 366 million people worldwide have diabetes, according to the CDC and 2011 data from the IDF. Type 2 diabetes accounts for 90-95[…]

Read More

DDP-4 inhibitors, commonly known as Gliptins, are a relatively new group of drugs. They are drugs normally used for diabetes control, however, this year it was discovered that they may play a greater heart-protective role in patients with existing cardiovascular comorbidities. According to the report published last month in Medpage Today, researchers found that patients[…]

Read More